Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Feb 22 2021 Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
- Feb 17 2021 Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
- Feb 2 2021 Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
- Jan 29 2021 Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock